Skip to main content
AS

Alexander Shulgin Research Institute

This organization focuses on psychedelics discovery, development, and education, extending the foundational work of Dr. Alexander Shulgin. The institute actively seeks to identify novel substances that induce psychedelic experiences in healthy human subjects. Furthermore, it is committed to developing new therapeutic compounds and associated delivery systems for clinical application.

Lafayette, United States
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

The development of novel therapeutics for neurological and psychiatric disorders is hindered by a lack of research into psychedelic compounds and their potential therapeutic applications. Traditional research methods can be limited in scope and may not fully explore the therapeutic potential of these substances.

Solution

The Alexander Shulgin Research Institute (ASRI) is dedicated to the discovery, development, and pharmacological evaluation of psychedelic substances for therapeutic use. ASRI synthesizes novel compounds, isolates natural products, and conducts basic pharmacological testing to identify substances with potential psychedelic activity and therapeutic benefits. The organization leverages the Shulgin Vault, a collection of approximately 500 compounds, to explore both natural products and novel analogs of known psychedelics in the phenylalkylamine, tryptamine, and lysergamide chemical classes. ASRI aims to advance the understanding of consciousness and develop new treatments for neurological, neurodevelopmental, neuropsychiatric disorders, pain syndromes, and inflammation.

Target Audience

ASRI serves academic researchers, clinical researchers, pharmaceutical companies, government agencies, and legal clients seeking expertise in psychedelic drug discovery, development, and analysis.

Features

  • Design and synthesis of novel psychedelic compounds
  • Isolation and identification of naturally occurring psychoactive compounds
  • Comprehensive cataloging and characterization of compounds from the Shulgin Vault
  • In vitro pharmacological profiling to identify drug binding sites and assess functional activity at various receptors, ion channels, and transporters
  • In vivo evaluation of behavioral and psychoactive effects in animal models
  • Supply of compounds to qualified scientists for preclinical and clinical research
  • Advanced analytical capabilities including GC/MS, LC/MS/MS, NMR, and X-ray diffraction analysis
This profile is AI-generated and may contain inaccuracies.